Patient Snapshot Bernard W. is a 43-year-old male presenting with severe, treatment-resistant constipation requiring stimulant laxatives (Ex-Lax 3x/week, senna 2x/week), biweekly enemas, and monthly colonics. He reported chronic bloating, abdominal discomfort, and fatigue that had not responded to multiple rounds of conventional SIBO treatment over several years. Mental health symptoms included persistent anxiety and brain fog that worsened in parallel with GI flares. Bernard had consulted numerous gastroenterologists and functional medicine practitioners, completed multiple breath tests and stool analyses, and tried various antimicrobial protocols—all without lasting improvement. He arrived with years of accumulated lab data from previous providers, seeking a fresh perspective on what everyone else had missed. Readiness for change: 10 out of 10.

Introduction

Bernard’s case challenges a common assumption in functional medicine: that comprehensive testing means ordering every available panel. Sometimes, the most powerful diagnostic approach is reviewing what’s already been done, identifying what’s missing, and targeting those specific gaps with precision.

When Bernard arrived at FxMed Mental Health, he brought years of lab results from previous providers—standard SIBO breath tests, stool analyses, blood panels, even genetic testing. He had been told he had SIBO, treated for SIBO, cleared on follow-up testing, and then relapsed. This cycle had repeated multiple times. The question wasn’t whether he had gut dysfunction—it was why nothing was working.

Our approach was different. Rather than repeating everything, we systematically analyzed his existing data, looking for patterns that might have been overlooked and identifying critical gaps in his diagnostic workup. Two tests emerged as essential: a three-gas breath test that could detect hydrogen sulfide (which standard two-gas tests miss entirely), and a blood test for autoimmune markers of gut motility dysfunction.

What we found transformed our understanding of his case—and opened a treatment pathway that no previous provider had considered. This is the story of how targeted, strategic testing uncovered hydrogen sulfide SIBO and autoimmune damage to the gut’s pacemaker system, finally explaining years of treatment failure.

The Diagnostic Approach: Working With What We Had

Bernard did not complete our standard FxMed Mental Health six-test bundle. After reviewing his history, it became clear that repeating tests he’d already done would waste time and money without yielding new insights. Instead, we took a different approach: analyze what exists, identify what’s missing, and order only what will change clinical decision-making.

What Bernard Had Already Done

His accumulated records included:

•  Multiple two-gas SIBO breath tests (hydrogen and methane only)—results fluctuated between positive and negative over the years

•  GI-MAP stool analysis showing elevated zonulin (173 ng/g, indicating intestinal permeability), low secretory IgA (384 μg/mL), elevated TGF-β1 (9,772 pg/mL), low pancreatic elastase (suggesting pancreatic insufficiency), and multiple opportunistic bacteria (Bacillus, Enterococcus, Morganella, Pseudomonas, Staphylococcus)

•  Basic serum panels with no major red flags

•  Genetic testing results

The Critical Gaps We Identified

Two glaring omissions stood out:

1. No hydrogen sulfide measurement. All of Bernard’s previous breath tests measured only hydrogen and methane—the standard two-gas approach used by most labs. But research by Dr. Mark Pimentel and colleagues at Cedars-Sinai has identified a third gas, hydrogen sulfide (H₂S), produced by sulfate-reducing bacteria. Approximately 25% of patients who test “normal” on standard breath tests have elevated hydrogen sulfide levels that explain their symptoms. The only breath test that measures H₂S is the Trio-Smart.

2. No assessment of autoimmune motility dysfunction. Bernard’s history—recurrent SIBO despite treatment, severe constipation, dependence on stimulant laxatives—pointed toward impaired gut motility. But no one had investigated why his motility was impaired. The IBS-Smart test measures anti-CdtB and anti-vinculin antibodies, which can identify autoimmune damage to the interstitial cells of Cajal—the pacemaker cells that generate the migrating motor complex (MMC). If the MMC is damaged, bacteria cannot be swept from the small intestine, and SIBO becomes inevitable regardless of how many antimicrobial courses are prescribed.

We ordered exactly two tests: the Trio-Smart three-gas breath test and the IBS-Smart autoimmune panel. The results rewrote Bernard’s entire clinical narrative.

Key Findings: The Missing Pieces Finally Revealed

The two targeted tests provided the breakthrough that years of conventional workup had missed.

Finding #1: Hydrogen Sulfide SIBO—The Invisible Overgrowth

The Trio-Smart breath test revealed a pattern that explained everything:

Gas	Bernard’s Values	Threshold	Result
Hydrogen (H₂)	12.04–14.60 ppm	<32.04 ppm	Normal
Methane (CH₄)	<4.03 ppm (undetectable)	<10.00 ppm	Normal
Hydrogen Sulfide (H₂S)	2.09–2.77 ppm (all timepoints)	<3.00 ppm (clinical concern ≥2.00)	Elevated*

On a standard two-gas test, Bernard would have been told he was “negative” for SIBO. Hydrogen didn’t reach the diagnostic threshold, and methane was completely undetectable. This is exactly what his previous tests had shown—and why clinicians kept concluding his SIBO had “resolved.”

But the Trio-Smart revealed what those tests couldn’t see: hydrogen sulfide was elevated throughout the entire 120-minute test, ranging from 2.09 to 2.77 ppm at every single timepoint. While technically below the official 3.00 ppm threshold, the lab itself flagged this result, noting that levels ≥2.00 ppm are “notably distinguishable from patients with constipation IBS” and warrant clinical attention.

The hydrogen sink phenomenon. Looking deeper at the hydrogen curve revealed another critical insight: hydrogen peaked at 14.60 ppm at 45 minutes, then dropped sharply to 5.83 ppm at 60 minutes—below Bernard’s own baseline. This pattern, sometimes called a “hydrogen sink,” occurs when sulfate-reducing bacteria (SRBs) consume hydrogen as their substrate, converting it to hydrogen sulfide in real-time. The SRBs were literally eating the hydrogen before it could be detected on breath testing.

This meant Bernard may have had active hydrogen-producing SIBO for years that was invisible on standard testing because the sulfate-reducing bacteria were consuming the evidence. Every “negative” breath test was a false negative. Every time he was told his SIBO had cleared, he still had an active overgrowth—just one that produced a different gas.

Why this matters for treatment: Hydrogen sulfide SIBO requires a fundamentally different antimicrobial approach than hydrogen or methane SIBO. Standard botanical protocols often include allicin (garlic extract) for methane-dominant cases—but garlic is a high-sulfur compound that can actually feed sulfate-reducing bacteria. If any of Bernard’s previous treatments included garlic-based antimicrobials, they may have worsened his condition while appearing to address it.

Finding #2: Autoimmune Damage to the Migrating Motor Complex

The IBS-Smart test provided the second breakthrough:

Antibody	Bernard’s Value (OD)	Result
Anti-CdtB	1.53 (reference <1.55)	Borderline (98th percentile)
Anti-Vinculin	2.29 (reference <1.59)	ELEVATED (44% above threshold)

Elevated anti-vinculin antibodies = confirmed autoimmune damage to the migrating motor complex.

The biology: At some point in Bernard’s past—likely the food poisoning episode he recalled from years ago—a pathogenic organism (commonly Campylobacter, Salmonella, or toxigenic E. coli) infected his gut. These organisms produce Cytolethal Distending Toxin B (CdtB) as part of their pathogenic mechanism. Bernard’s immune system mounted an appropriate antibody response against CdtB. Unfortunately, CdtB shares structural similarity with vinculin—a protein highly expressed in the interstitial cells of Cajal (ICC), the pacemaker cells of the gut.

Through a process called molecular mimicry, Bernard’s immune system began cross-reacting with his own vinculin. The result: ongoing autoimmune attack on the ICC—the very cells that generate the migrating motor complex.

The pattern tells a story. Bernard’s anti-CdtB was at the 98th percentile of the reference range—borderline elevated. His anti-vinculin was definitively elevated at 44% above threshold. This specific pattern—declining CdtB with persistently elevated vinculin—indicates the triggering infection likely occurred years ago (anti-CdtB antibodies fade over time as the pathogen is cleared), but the autoimmune damage it set in motion continues because the antigen (vinculin in ICC) is always present.

This is why his SIBO keeps coming back. The MMC is supposed to sweep bacteria from the small intestine between meals—a “housekeeper wave” that fires approximately every 90-120 minutes during fasting. When the ICC are damaged, the MMC cannot fire properly. Bacteria that should be cleared accumulate and overgrow. No amount of antimicrobial treatment will permanently resolve SIBO if the underlying motility dysfunction isn’t addressed. The bacteria will simply repopulate.

Integrating the Existing Lab Data

With the two missing pieces now in place, Bernard’s existing lab results suddenly made coherent sense:

Elevated zonulin (173 ng/g): Hydrogen sulfide is directly cytotoxic to intestinal epithelial cells and disrupts tight junction proteins. A persistent population of sulfate-reducing bacteria producing H₂S at the mucosal surface was a significant driver of his intestinal permeability.

Low sIgA (384 μg/mL): Chronic mucosal inflammation from H₂S exposure contributes to secretory IgA depletion through ongoing immune exhaustion.

Elevated TGF-β1 (9,772 pg/mL): Chronic mucosal exposure to H₂S triggers inflammatory cascades and tissue remodeling responses. This elevation likely reflected gut-driven inflammation rather than the mycotoxin exposure we initially considered.

Severe constipation despite zero methane: Methane-producing archaea are classically associated with constipation, but Bernard’s methane was undetectable. His constipation was driven by ICC dysfunction (autoimmune MMC damage), not by methanogens. Sulfate-reducing bacteria and methanogens compete for the same substrate (hydrogen), so SRB dominance explains the complete absence of methane.

Multiple opportunistic bacteria on GI-MAP: An SRB-dominant ecology disrupts normal microbial community structure, creating an environment permissive to opportunistic colonization.

Connecting the Dots: SIBO and Mental Health

Bernard’s case illustrates the profound connection between gut dysfunction and mental health—a relationship increasingly supported by research on the gut-brain axis.

Hydrogen sulfide is a gasotransmitter. Unlike inert gases, H₂S is a neuroactive signaling molecule. Chronic H₂S exposure at the mucosal surface modulates vagal afferent signaling—the direct communication highway between gut and brain. Elevated H₂S can contribute to visceral hypersensitivity, anxiety, and cognitive symptoms through direct neurological mechanisms.

Intestinal permeability drives neuroinflammation. Bernard’s elevated zonulin indicated compromised gut barrier function. When the intestinal barrier is breached, endotoxin (LPS) translocates into systemic circulation, triggering inflammatory cascades that reach the brain. This process—sometimes called “leaky gut, leaky brain”—has robust links to neuroinflammation, depression, and anxiety in the research literature.

Sulfate-reducing bacteria can alter neurotransmitter precursors. SRBs have been shown to affect tryptophan metabolism, potentially diverting tryptophan away from serotonin synthesis. Combined with the chronic inflammation reflected in his elevated TGF-β1, Bernard’s gut dysfunction was creating the biological substrate for persistent anxiety and brain fog.

This is why functional medicine for mental health must extend beyond the brain. Bernard’s anxiety and cognitive symptoms weren’t “all in his head”—they were downstream consequences of gut dysfunction that had gone undiagnosed for years. Addressing the root cause meant addressing the gut first.

Treatment Protocol: A Different Approach

Bernard’s treatment protocol had to address two distinct but interconnected problems: (1) the autoimmune damage to his motility system, and (2) the hydrogen sulfide-producing bacterial overgrowth. Critically, the protocol had to address them in the correct sequence—and avoid the sulfur-based interventions that previous protocols had likely included.

Working With Insurance Realities

Our initial prescription strategy included Motegrity (prucalopride), a 5-HT4 receptor agonist that directly stimulates colonic motility. Insurance denied coverage. The alternative, Ibsrela (tenapanor), which had shown promise for both constipation and intestinal barrier support, was also denied.

What insurance approved was Linzess (linaclotide)—a GC-C agonist that works through different mechanisms but achieves similar clinical goals: increased intestinal fluid secretion, faster transit time, and reduced visceral pain. While we lost some of the specific barrier-repair properties of our preferred agents, Linzess provided adequate motility support to proceed with the protocol.

This is the reality of clinical practice: we work with what’s available, not just what’s ideal. The key was ensuring Bernard had effective motility support—the specific agent mattered less than achieving the functional goal.

After significant effort, Bernard was also able to obtain low-dose naltrexone (LDN) through a compounding pharmacy. This became the cornerstone of his prokinetic strategy, offering dual benefits: direct MMC stimulation and immune modulation that may help calm the autoimmune component driving his ICC damage.

Phase 1: Motility Restoration and Foundation (Weeks 1-8)

Before introducing antimicrobials, we needed to restore functional motility and begin transitioning Bernard off stimulant laxatives. The gate for proceeding to Phase 2 was non-negotiable: daily spontaneous bowel movements without Ex-Lax or senna.

The logic: if dead bacteria and their toxins cannot be eliminated efficiently due to constipation, antimicrobial therapy creates a situation where die-off reactions are severe and potentially harmful. Motility had to work first.

Phase 1 Protocol Highlights:

•  Linzess 145-290 mcg, 30 minutes before breakfast on empty stomach

•  LDN titrating from 1.5 mg to 4.5 mg at bedtime over 4 weeks

•  Magnesium citrate 300 mg at bedtime (osmotic support)

•  Ginger extract 1000 mg at bedtime (prokinetic support)

•  Digestive enzymes with Betaine HCl with meals (addressing pancreatic insufficiency)

•  Serum bovine immunoglobulins (SBI) 2.5-5g with breakfast (mucosal immune support)

•  Zinc carnosine 75 mg with breakfast (tight junction support)

•  Vitamin D3/K2 5,000 IU with dinner (immune modulation)

Phase 2: Hydrogen Sulfide-Targeted Antimicrobial Protocol (Weeks 9-14)

Once motility was established, we introduced a targeted antimicrobial strategy specifically designed for hydrogen sulfide SIBO—fundamentally different from standard hydrogen or methane protocols.

The cornerstone: Bismuth subsalicylate (Pepto-Bismol).

Research shows bismuth compounds are uniquely effective against hydrogen sulfide SIBO. A case registry of H₂S SIBO patients found that only two interventions were significantly associated with treatment response: a low-sulfur diet (73% responder rate) and bismuth (76% responder rate). Bismuth binds H₂S directly (providing rapid symptom relief) while also exerting antimicrobial effects against sulfate-reducing bacteria.

Phase 2 Antimicrobial Stack:

•  Bismuth subsalicylate 524 mg (2 tablets) three times daily with meals

•  Oregano oil (emulsified) 150-200 mg twice daily

•  Berberine 500 mg twice daily

•  Molybdenum 250-500 mcg daily (supports sulfite-to-sulfate conversion, reduces die-off)

•  Biofilm-disrupting enzymes 30 minutes before meals (SRBs form robust biofilms)

Critical: What we AVOIDED

No allicin (garlic extract), NAC, alpha-lipoic acid, glutathione, MSM, taurine, or SAMe. All of these contain sulfur compounds that could feed sulfate-reducing bacteria—the exact organisms we were trying to eliminate. We also implemented a temporary low-sulfur diet, reducing cruciferous vegetables, alliums (garlic, onions), eggs, and high-sulfur proteins during the active antimicrobial phase.

Phase 3: Repair, Rebalance, and Long-Term Maintenance (Ongoing)

After the antimicrobial phase, focus shifted to rebuilding a healthy microbiome, completing gut barrier repair, and establishing the long-term maintenance strategy Bernard will need given his confirmed autoimmune MMC damage.

Phase 3 Highlights:

•  Spore-based probiotics (starting low, titrating up)

•  Saccharomyces boulardii (shown to reduce SIBO recurrence by 80% when combined with standard care)

•  Gradual sulfur food reintroduction (one food category per week, monitoring for symptom return)

•  Omega-3 fatty acids for inflammation resolution

•  Continued LDN, Linzess, and magnesium as long-term infrastructure

The critical reframe: Given Bernard’s confirmed anti-vinculin elevation, LDN and prokinetic support are not temporary interventions. His ICC damage from autoimmune attack is likely permanent to some degree. We cannot “cure” this in the sense of restoring his gut to its pre-infection state. What we can do is manage the motility dysfunction effectively, prevent SIBO recurrence, and give him a sustainable path to symptom control. This is long-term management of a chronic condition, not a finite treatment course.

Clinical Response

Treatment is ongoing, and it is too early to declare victory. But early indicators are encouraging.

Early Outcomes •  Bernard has expressed hope for the first time in years—a psychological shift from resignation to active engagement •  He reports understanding his condition in a way that previous providers never explained—the autoimmune MMC damage and H₂S findings gave him a coherent narrative for his suffering •  LDN and Linzess are now on board; stimulant laxative transition is in progress •  Full adherence to the protocol despite its complexity

We anticipate measurable improvement in digestive symptoms by the end of Phase 2, with downstream improvements in energy, mood, and cognition following as the gut-brain axis normalizes. Repeat Trio-Smart testing is planned 4-6 weeks after completing the antimicrobial phase to confirm H₂S normalization.

Clinical Considerations and Controversies

The Emerging Science of Hydrogen Sulfide SIBO

Hydrogen sulfide SIBO is a relatively new diagnostic entity. The Trio-Smart breath test became available commercially only in recent years, and the 3.00 ppm threshold (and 2.00 ppm clinical concern threshold) are based on emerging data, not decades of validation. We are making clinical decisions in a zone where the science is evolving rapidly.

The “hydrogen sink” hypothesis—that sulfate-reducing bacteria consume hydrogen, masking standard breath test results—is mechanistically sound and supported by the literature, but interpreting Bernard’s specific curve as evidence of this phenomenon is inferential. It is the most parsimonious explanation given the full clinical picture, but it cannot be confirmed from breath data alone.

Additionally, the Trio-Smart was performed using glucose as the substrate, which is absorbed in the proximal small intestine. If significant SRB colonization exists in the distal small intestine or proximal colon, a glucose test would underestimate the true H₂S burden. Bernard’s actual hydrogen sulfide load may be higher than what the test revealed.

Autoimmune IBS: A Paradigm Shift

The recognition that a subset of IBS/SIBO cases have an autoimmune etiology—post-infectious antibodies cross-reacting with gut motility proteins—represents a significant paradigm shift. For decades, IBS was considered a “functional” disorder with no identifiable organic pathology. The discovery of anti-vinculin and anti-CdtB antibodies provides a measurable, organic explanation for a subset of these patients.

That said, the IBS-Smart test has limitations. Not all post-infectious IBS patients will test positive (sensitivity is estimated at 60-70%), and the test does not predict treatment response. A positive anti-vinculin result confirms the etiology but does not guarantee that prokinetic therapy will restore normal function. Bernard’s ICC may be damaged beyond what pharmacological support can fully compensate for.

Bismuth Safety and Duration

Bismuth subsalicylate is a well-tolerated over-the-counter medication, but extended use (beyond 8 weeks) at therapeutic doses warrants caution. Rare cases of bismuth encephalopathy have been reported with very prolonged, high-dose use. The salicylate component is relevant for patients on blood thinners or with aspirin sensitivity. For Bernard, we planned a 6-week course with reassessment—long enough for antimicrobial effect, short enough to minimize risk.

The Value of Strategic, Targeted Testing

Bernard’s case demonstrates that comprehensive testing doesn’t always mean more testing. He had been tested extensively by previous providers—but the wrong tests, or tests that couldn’t answer the critical questions. Two targeted tests (Trio-Smart and IBS-Smart), ordered specifically to fill identified gaps, provided more clinical value than years of prior workup.

This approach—review existing data, identify gaps, order only what changes management—is both cost-effective and clinically efficient. It also demonstrates respect for the patient’s time, resources, and testing fatigue after years of inconclusive workups.

Conclusion

Bernard’s case illustrates a central principle of functional medicine for hydrogen sulfide SIBO and treatment-resistant gut dysfunction: when standard approaches fail repeatedly, the problem isn’t usually patient compliance or treatment inadequacy—it’s missed diagnosis.

For years, Bernard was told he had SIBO, treated for SIBO, cleared on follow-up testing, and then relapsed. The cycle repeated because no one tested for the third gas (hydrogen sulfide) or asked why his motility was so profoundly impaired. Two targeted tests revealed the complete picture: an autoimmune attack on his gut’s pacemaker cells, triggered by food poisoning years ago and continuing silently ever since, combined with hydrogen sulfide-producing bacteria that were invisible on standard breath tests.

This understanding transformed his treatment approach. Instead of another round of standard antimicrobials that would temporarily suppress symptoms before inevitable relapse, Bernard now has a protocol specifically designed for his H₂S-dominant ecology (bismuth-centered, no sulfur compounds) combined with long-term prokinetic support for his damaged MMC.

The connection between SIBO and mental health is not abstract—it’s biological. Hydrogen sulfide is neuroactive. Intestinal permeability drives neuroinflammation. Dysbiosis disrupts neurotransmitter precursor production. Bernard’s anxiety and brain fog weren’t separate problems requiring separate psychiatric treatment; they were downstream consequences of the same gut dysfunction that caused his constipation and bloating. Addressing the root cause meant addressing everything at once.

Treatment is ongoing. Full resolution will require months, not weeks. But for the first time in years, Bernard has a coherent explanation for his suffering, a targeted treatment plan designed for his specific pathophysiology, and—most importantly—hope that this time might be different.

Sometimes the most powerful diagnostic tool isn’t ordering more tests—it’s looking at what’s already been done and asking: what did everyone miss?